1. Home
  2. Knowledge Base
  3. References
  4. Donepezil enhances effects of estradiol on DMP acquisition in rats with partial loss of septal cholinergic neurons

Donepezil enhances effects of estradiol on DMP acquisition in rats with partial loss of septal cholinergic neurons

Gibbs RB, Chipman AM, Nelson D (2010) Donepezil enhances effects of estradiol on DMP acquisition in rats with partial loss of septal cholinergic neurons. Neuroscience 2010 Abstracts 710.23/NNN23. Society for Neuroscience, San Diego, CA.

Summary: We hypothesize that effects of estradiol on cognitive performance decrease in association with decreased basal forebrain cholinergic function, and that this accounts for the loss of estradiol effect with age and time post-menopause. In the present study, we tested the feasibility of using donepezil, a cholinesterase inhibitor commonly used to treat Alzheimer’s disease, to enhance beneficial effects of estradiol on cognitive performance in rats with septal cholinergic lesions. Young adult, ovariectomized rats received intraseptal injections of 192IgG-saporin or vehicle. Two weeks later, rats started receiving daily injections of donepezil (Don, 5 mg/Kg/day, i.p.) or vehicle. A week later, rats received either silastic capsules containing 17ß-estradiol (E) or empty capsules, implanted s.c. Rats were then trained on a delayed matching-to-position (DMP) T-maze task. Upon completion, brains were collected and sections through the medial septum were processed for detection of choline acetyltransferase (ChAT). The severity of the cholinergic lesions was ranked on a 5-point scale by estimating the loss of ChAT-positive cells in the septum. Eighty-one rats completed the study. Lesions produced a decline in performance that correlated with the severity of cholinergic cell loss (F[4,76]=10.0, p<0.0001). In rats with >50% loss of septal cholinergic neurons, treating with E and/or Don had no significant effect on the rate of DMP acquisition (F[3,36]=0.90, p=0.45). In rats with <50% loss of septal cholinergic neurons, treating with the combination of Don+E significantly increased the rate of acquisition relative to controls (p<0.05 by Tukey test), and reduced deficits associated with increasing the intertrial delay (F[9, 111]=2.30, p=0.02 for Delay x Tx interaction). Treating with Don or E alone had no significant effect, although E alone produced a strong trend toward improvement. Cholinergic lesions also increased the likelihood that rats would adopt a persistent turn χ2=13.3, p=0.0003), and treatment with Don+E reduced this effect (χ2=8.8, p=0.03). These findings demonstrate that cholinergic dysfunction produces a learning impairment as well as a loss of estrogen effect on cognitive performance which can be attenuated by treating with a cholinesterase inhibitor. The findings also indicate a critical threshold for cholinergic function below which combined therapy is not effective. We propose that combining donepezil with estrogen therapy in postmenopausal women may offer significant cognitive benefits, particularly in relatively healthy older women showing early signs of cognitive impairment or Alzheimer’s disease.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Shopping Cart
Scroll to Top